Back

Integrative Multiomic Analysis Reveals How Non-Viral Delivery System Selection Shapes CRISPR Gene Editing Outcomes in Stem Cells.

Graham, J. P.; Arteaga, A. V.; Moghaddam, A. S.; Spiller, K. L.; Laverty, D. J.; Gonzalez-Fernandez, T.

2026-05-30 bioengineering
10.64898/2026.05.29.728905 bioRxiv
Show abstract

The clinical translation of CRISPR gene editing is challenged by the lack of delivery systems that are both safe and efficient in therapeutically relevant cell types such as mesenchymal stem cells (MSCs). Non-viral delivery avoids the immunogenicity and genomic integration risks of viral vectors but faces fundamental trade-offs between editing efficiency and cytotoxicity. Here, we present a comprehensive multiomic analysis of four non-viral CRISPR delivery modalities including cell-penetrating peptide- (CPP), lipid-, and polymer-based nanoparticles and electroporation; across mRNA and ribonucleoprotein (RNP) molecular formats. We systematically evaluate each modality, demonstrating that lipid-based delivery achieved the highest editing rates at the cost of genomic instability risks, interferon pathway activation, and a pro-inflammatory shift in MSC paracrine activity. Alternatively, CPPs yield moderate editing rates while reducing these unintended side-effects, whereas polymers and electroporation consistently yielded the lowest efficiencies. CRISPR molecular format and delivery method interacted in a stress-dependent manner, with RNP delivery reducing editing rates under high-stress systems while improving them in lower-stress modalities such as CPP and electroporation. These findings establish that editing efficiency alone is an insufficient metric for delivery system selection, and that genomic stability, transcriptomic dysregulation, and inflammatory response must be treated as primary design criteria for CRISPR therapies.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Molecular Therapy Nucleic Acids
39 papers in training set
Top 0.1%
26.4%
2
Molecular Therapy - Methods & Clinical Development
38 papers in training set
Top 0.1%
7.2%
3
Advanced Science
286 papers in training set
Top 0.9%
6.2%
4
Molecular Therapy
81 papers in training set
Top 0.3%
6.2%
5
Journal of Controlled Release
44 papers in training set
Top 0.2%
5.5%
50% of probability mass above
6
Nature Communications
5641 papers in training set
Top 29%
5.1%
7
Nature Biomedical Engineering
47 papers in training set
Top 0.4%
3.1%
8
Advanced Functional Materials
46 papers in training set
Top 0.6%
2.1%
9
Nature Biotechnology
172 papers in training set
Top 2%
2.1%
10
Scientific Reports
3612 papers in training set
Top 48%
2.1%
11
Bioengineering & Translational Medicine
21 papers in training set
Top 0.3%
1.7%
12
ACS Synthetic Biology
287 papers in training set
Top 1%
1.7%
13
Proceedings of the National Academy of Sciences
2444 papers in training set
Top 30%
1.5%
14
Frontiers in Bioengineering and Biotechnology
98 papers in training set
Top 1%
1.5%
15
ACS Chemical Biology
167 papers in training set
Top 2%
1.5%
16
Journal of Biological Engineering
12 papers in training set
Top 0.1%
1.1%
17
Trends in Biotechnology
12 papers in training set
Top 0.1%
1.1%
18
Small
78 papers in training set
Top 1%
1.1%
19
Science Advances
1243 papers in training set
Top 25%
1.1%
20
Molecular Therapy - Nucleic Acids
25 papers in training set
Top 0.5%
1.0%
21
Biomaterials
84 papers in training set
Top 1%
1.0%
22
eLife
5828 papers in training set
Top 62%
1.0%
23
Analytical Chemistry
218 papers in training set
Top 2%
1.0%
24
Bioactive Materials
20 papers in training set
Top 0.5%
0.8%
25
PLOS ONE
5266 papers in training set
Top 61%
0.8%
26
Stem Cell Reports
130 papers in training set
Top 2%
0.8%
27
JCI Insight
277 papers in training set
Top 9%
0.6%
28
Cell Reports Physical Science
19 papers in training set
Top 0.3%
0.6%